FABP4 and metabolic dysfunction-associated steatohepatitis: FABP4, as implicated in diabetes-induced MAFLD, represents a promising target for future studies aimed at developing therapeutic interventions for MAFLD or strategies to prevent the progression to NASH and liver fibrosis.